Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands  by Uttenthal, L.O. & Blázquez, E.
Volume 262, number 1, 139-141 FEBS 08228 March 1990 
Characterization of high-affinity receptors for truncated glucagon-like 
peptide-l in rat gastric glands 
L.O. Uttenthal and E. Blkzquez 
Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universidad Complutense de Madrid, Ciudad Universitaria, 
E-28040 Madrid, Spain 
Received 22 January 1990 
The truncated form of glucagon-like peptide-l (TGLP-I, or proglucagon 78-IO@, secreted by the mammalian i testine, has potent pharmacological 
activities, stimulating insulin release and inhibiting gastric acid secretion. We have characterized high-athnity receptors for this peptide in rat isolated 
fimdic glands. Scatchard analysis of binding studies using mono- rz51-TGLP-1(7-36) amide as tracer showed a single class of binding site of & 
(4.4k(SE) 0.8) x lo-r0 M, with a tissue concentration of 1.0 f 0.1 fmol sites/pg DNA. Whole GLP-1 was approximately 700 times less potent 
in displacing tracer, while human GLP-2 and pancreatic glucagon produced no significant displacement at concentrations up to 1Om6 M. The data 
support a physiolo~~l role for TGLP-1 in the regulation of gastric acid secretion. 
Receptor; Proglucagon 78-108; Gastric mucosa; Fundic gland 
1 s INTRGDUCT~ON 
Glucagon-like peptide-l (GLP-1) is one of two 
glucagon-like peptide sequences found in the C- 
terminal portion of mammalian proglucagon [ 1,2]. 
Whereas these peptides are produced in the free form 
by post-translational processing in human, porcine 
[3,4] and rat [5] intestine, the pancreas produces mainly 
a larger fragment consisting of the two peptides linked 
by a spacer peptide [3,6]. However, only a fraction 
(about 40%) of the total GLP-1 produced by human 
and rat intestine occurs as the entire GLP-1 sequence 
(proglucagon 72-108), most of the rest being accounted 
for by a fragment produced by removal of the first 6 
amino acid residues of GLP-1, resulting in a truncated 
form, TGLP-1 (proglucagon 78-108) [5,7]. This pep- 
tide is released into the circulation postprandially 171, 
and has potent biological activities both in stim~ating 
glucose-dependent insulin secretion [8] and in in- 
hibiting pentagastrin-stimulated gastric acid secretion 
in man [9]. It is still uncertain to what extent, if any, 
the C-terminus is amidated, but the amidated and C- 
terminal glycine forms are approximately equipotent in 
the rat isolated pancreas 181. Specific receptors for 
TGLP-1 have been described in rat insulinoma 
(RINmSF) cells [lo], but not in gastric mucosa, 
although a stimulatory effect of TGLP-1 on CAMP 
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production by rat isolated fundic glands and human 
gastric cancer cells has been reported [9]. We have 
therefore characterized the gastric receptor for TGLP-1 
by means of direct binding studies in rat isolated fundic 
glands. 
2. MATERIALS AND METHODS 
2.1. Peptides and label 
Synthetic TGLP-1 in the amide form (proglucagon 78-107 amide), 
GLP-1 (proglucagon 72-107 amide) and human GLP-2 were from 
Peninsula Laboratories (Belmont, CA, USA). Pure pancreatic 
glucagon was from Eli Lilly and Co. (Indianapolis, IN, USA). 
TGLP-I was trace-labelled with “‘1 (Amersham International PLC, 
Amersham, Bucks, England) by the chloramine-T method [ll], and 
mono-iz51-TGLP-1 was isolated by gel filtration on BioGel P-30 
followed by reverse-phase I-IPLC on a Cis column using a shallow 
gradient of acetonitrile in water [lo]. The specific activity of the label 
was calculated as 58 Bq/fmol. 
2.2. Tissue preparation 
Gastric mucosal glands were collected as described [12] from the 
fundic portion of everted stomachs of male Wistar rats (200-300 g) 
that had free access to commercial food pellets and water. EDTA (2.5 
mM) in hypertonic saline (0.25 M NaCl) was used to separate the 
glands. The DNA content of aliquots was determined by Burton’s 
method [13]. with calf thymus DNA as standard. 
2.3. Incubations 
Glands were washed and suspended in Krebs-Ringer-phosphate 
buffer, pH 7.5. Incubations of glands (3-5 mg wet weight or 11-16 
pg DNA/tu~) with labelled TGLP-I(40 PM) andfor unlabelled pep- 
tides (10-1’-10-6 M) were carried out in triplicate in the same buffer 
containing final concentrations of BSA 10 mg/ml and bacitracin 0.7 
mg/ml, as described [14]. Glands were separated by rapid ceutrifuga- 
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tion and washed once with incubation buffer for counting of bound 
radioactivity. 
TO determine tracer degradation, incubation supernatants were 
reincubated with fresh glands and the percentage of binding of 
radioactivity compared with that of controls incubated with the same 
concentration of fresh label under identical conditions. Tracer 
degradation was also determined from the increase in the percentage 
of non-precipitable radioactivity after treating incubation super- 
natants and control solutions of fresh label with trichloroacetic acid 
to a final concentration of 10%. 
CAMP production was determined after 1 h incubation at 20°C in 
the presence of IBMX 0.5 mM. Incubation was terminated by the ad- 
dition of trichloroacetic acid, and supernatants were extracted with 
diethyl ether for determination of CAMP by radioimmunoassay [1.5]. 
3. RESULTS 
Binding of mono- 12%TGLP-l to rat fundic glands 
was time and temperature dependent (fig.1). As 
unlabelled TGLP-1 was almost as effective in inhibiting 
tracer binding at lo-’ M as at lOa M, the lower con- 
centration of unlabelled peptide was used to 
demonstrate the difference between total and non- 
specific binding in these time-course studies. Specific 
binding reached a plateau in 2 h at 2O”C, whereas at 
37°C no approximation to equilibrium was achieved. 
Studies of tracer degradation by reincubation of super- 
natants with fresh glands showed that this could at least 
in part be att~buted to rapid degradation of tracer, 
which was 30-34% (n = 3) degraded in 2 h at 37”C, 
compared with 12-18010 at20°C. Degradation of tracer 
as measured by trichloroacetic acid precipitation was 
also appreciably higher at 37°C than at 20°C (4.7% 
and 2.1% at 2 h, respectively). Specific binding at 20°C 
was linearly proportional to tissue concentration up to 
a concentration of 22 mg 
shown). 
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Fig. 1. Binding and degradation of ‘ZSI-TGLP-l by rat fundic glands 
(mean f SE, n = 3). Upper panels show time-course of binding in 
the presence and absence of unlabelled TGLP-1 IO-* M at 20°C and 
37”C, and lower panels show the corresponding degradation of label 
as determined by rebinding studies and t~c~oroacetic acid 
precipitation. 
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Fig.2. Inhibition of specific binding of ‘%TGLP-1 to rat fundic 
glands by unlabelled TGLP-1 (e), whole GLP-1 (m), human GLP-2 
(A) and pancreatic glucagon (‘I). Incubations were carried out for 
2 h at 20°C. Data points show means f SE, n = 4. BO is the specific 
binding of radioactivity in the absence of unlabelled peptides, and 
specific binding (B) is defined as the totai binding of label minus the 
binding in the presence of unlabelled TGLP-1 10T6 M. 
Specific tracer binding was inhibited in a 
concentration-dependent manner by unlabelled 
TGLP-1. Whole GLP-I was approximately 700 times 
less potent in displacing the tracer, while human GLP-2 
and pancreatic glucagon produced no significant 
displacement at concentrations up to 10F6 M (fig.2). 
Scatchard analysis (fig.3) was compatible with a single 
class of binding site for TGLP-I Of Kd (4.4 + (SE) 0.8) 
x lo- lo M (n = 4), and a tissue concentration of bind- 
ing sites of 1.0 f {SE) 0.1 fmollpg DNA. 
TGLP-1 stimulated CAMP synthesis in the fundic 
glands with an EC50 of 1.6 x 10m9 M (fig.4). 
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Fig.3. Example of Scatchard plot of TGLP-1 binding to rat fundic 
glands. Data points show mean + SE of triplicates. 
140 
Volume 262, number 1 FEBS LETTERS March 1990 
2o”c 
i, ” lo i B i i 
[TGLP-1) , -log M 
Fig.4. Stimulation by TGLP-1 of CAMP production in rat fundlc 
glands. Cyclic AMP was determined after 1 h incubation at 20°C in 
the presence of IBMX 0.5 mM. Data points show mean f SE of 
triplicates from one of 3 similar determinations. 
4. DISCUSSION 
These data demonstrate the presence in rat fundic 
glands of high-affinity receptors for TGLP-1, whose 
activation is linked to the stimulation of CAMP syn- 
thesis. The receptors are comparable to those described 
in rat insulinoma-derived RINmSF cells in showing a 
single class of binding site [lo], but their affinities for 
both TGLP-1 and whole GLP-1 are slightly lower (& 
for TGLP-1 in RINmSF cells was 2 x lo-” M [lo]). 
Whether this is due to a difference in primary structure 
or to an environmentally determined influence on 
receptor conformation will become apparent when the 
receptor is isolated. The Kd reported here would never- 
theless permit a degree of receptor activation at 
physiological postprandial plasma concentrations of 
TGLP-1, which may reach lo- lo M in human subjects 
171. 
It has been proposed that the effect of high doses of 
pancreatic glucagon to inhibit gastric acid secretion and 
stimulate CAMP synthesis in rat fundic glands may be 
mediated via the TGLP-1 receptor [9]. So far, our data 
do not support this view. The specificities of the recep- 
tor(s) that are activated by high concentrations of 
glucagon require further elucidation. It is a matter for 
speculation whether glucagon or other products of the 
glucagon precursor may exert a paracrine effect in the 
gastric mucosa of those species that have a significant 
number of glucagon-secreting cells in the stomach. It is 
at present not known whether these gastric A cells are 
capable of producing appreciable amounts of free 
TGLP-1. 
As both the stimulatory effect of histamine and the 
inhibitory effect of TGLP-1 on gastric acid secretion 
appear to be associated with increased CAMP synthesis, 
it is apparent that the precise role of CAMP in the ac- 
tion of TGLP-1 in the gastric mucosa remains to be 
determined. It is not known which type of cell is 
responsible for the TGLP-l-induced CAMP produc- 
tion, but it has been suggested that it may be related to 
mucus secretion, while the inhibitory effect on gastric 
acid secretion may be mediated by other mechanisms 
PI. 
The present results contribute to a picture of TGLP-1 
as a postprandial hormone of considerable importance, 
not only in ensuring adequate insulin secretion as a part 
of the endocrine entero-insular axis [7], but also play- 
ing its part in switching off gastric acid secretion during 
the intestinal phase of digestion. It is thus a strong can- 
didate for fulfilling the role of the classically described 
‘enterogastrone’. 
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